Celldex Therapeutics Inc

$21.21
(as of Jun 16, 10:45 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Celldex Therapeutics Inc

Stock Price
$21.21
Ticker Symbol
CLDX
Exchange
NASDAQ

Industry Information for Celldex Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Celldex Therapeutics Inc

Country
USA
Full Time Employees
186

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Fundamentals for Celldex Therapeutics Inc

Market Capitalization
$1,355,769,984
EBITDA
$-213,940,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-2.69
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
66,394,200
Percent Owned by Insiders
0.32%
Percent Owned by Institutions
113.13%
52-Week High
52-Week Low

Technical Indicators for Celldex Therapeutics Inc

50-Day Moving Average
200-Day Moving Average
RSI
57.88
1.42

Analyst Ratings for Celldex Therapeutics Inc

Strong Buy
10
Buy
2
Hold
2
Sell
0
Strong Sell
0

News About Celldex Therapeutics Inc

Jun 16, 2025, 7:27 AM EST
Jun 14, 2025, 11:00 AM EST
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU See more.
Jun 14, 2025, 10:48 AM EST
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU See more.
Jun 14, 2025, 10:48 AM EST
Celldex Therapeutics, Inc. See more.